One-Year Outcomes from the TAXUS Express Stent Versus Cypher Stent

American Journal of Cardiology

Volumn 103, Issue 7, 2009, Pages 930-936

  Mayor, Manuel ^a   Malik, Amir Z ^b   Minor Jr , Robert J ^c   Deshpande, Mahesh C ^d   Strauss, William E ^d   Maloney, Thomas H ^d   Baim, Donald S ^d   O'Neill, William ^a   Kandzari, David E ^e  

^a UNIVERSITY OF MIAMI   (United States)

^b Heart Center of North Texas   (United States)

^c OSF Saint Anthony Medical Center   (United States)

^d BOSTON SCIENTIFIC CORPORATION   (United States)

^e SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAFETY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; POSTOPERATIVE COMPLICATIONS; PROSTHESIS DESIGN; RETROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 62849117773     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.11.052     Document Type: Article

References (25)

1. Cox D. Regression models and life-tables. J R Stat Soc Ser B 34 (1972) 187-220
2. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127 (1997) 757-763
3. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
4. Billinger M., Beutler J., Taghetchian K.R., Remondino A., Wenaweser P., Cook S., Togni M., Seiler C., Stettler C., Eberli F.R., et al. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 29 (2008) 718-725
5. Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., and Schomig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
6. Morice M.C., Colombo A., Meier B., Serruys P., Tamburino C., Guagliumi G., Sousa E., and Stoll H.P. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904
7. Galloe A.M., Thuesen L., Kelbaek H., Thayssen P., Rasmussen K., Hansen P.R., Bligaard N., Saunamaki K., Junker A., Aaroe J., et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 299 (2008) 409-416
8. Kastrati A., Mehilli J., von Beckerath N., Dibra A., Hausleiter J., Pache J., Schuhlen H., Schmitt C., Dirschinger J., and Schomig A. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
9. Goy J.J., Stauffer J.C., Siegenthaler M., Benoit A., and Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 45 (2005) 308-311
10. Simonton C.A., Brodie B., Cheek B., Krainin F., Metzger C., Hermiller J., Juk S., Duffy P., Humphrey A., Nussbaum M., and Laurent S. Comparative clinical outcomes of paclitaxel- and sirolimus-eluting stents: results from a large prospective multicenter registry-STENT Group. J Am Coll Cardiol 50 (2007) 1214-1222
11. Kaiser C., Brunner-La Rocca H.P., Buser P.T., Bonetti P.O., Osswald S., Linka A., Bernheim A., Zutter A., Zellweger M., Grize L., and Pfisterer M.E. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 366 (2005) 921-929
12. Kirtane A.J., Ellis S.G., Dawkins K.D., Colombo A., Grube E., Popma J.J., Fahy M., Leon M.B., Moses J.W., Mehran R., and Stone G.W. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 51 (2008) 708-715
13. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
14. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., Schomig A., Pfisterer M.E., Stone G.W., Leon M.B., de Lezo J.S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
15. Lee S.W., Park S.W., Kim Y.H., Yun S.C., Park D.W., Lee C.W., Hong M.K., Kim H.S., Ko J.K., Park J.H., et al. Drug-eluting stenting followed by cilostazol treatment decreases late restenosis in patients with diabetes mellitus: the DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 51 (2008) 1181-1187
16. Dibra A., Kastrati A., Mehilli J., Pache J., Schuhlen H., von Beckerath N., Ulm K., Wessely R., Dirschinger J., and Schomig A. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 353 (2005) 663-670
17. Kim M.H., Hong S.J., Cha K.S., Park H.S., Chae S.C., Hur S.H., Gwon H.C., Bae J.H., and Lim D.S. Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J Interv Cardiol 21 (2008) 225-231
18. Kuchulakanti P.K., Chu W.W., Torguson R., Clavijo L., Wolfram R., Mishra S., Xue Z., Gevorkian N., Suddath W.O., Satler L.F., et al. Sirolimus-eluting stents versus paclitaxel-eluting stents in the treatment of coronary artery disease in patients with diabetes mellitus. Am J Cardiol 98 (2006) 187-192
19. Stankovic G., Cosgrave J., Chieffo A., Iakovou I., Sangiorgi G., Montorfano M., Airoldi F., Carlino M., Michev I., Finci L., and Colombo A. Impact of sirolimus-eluting and paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol 98 (2006) 362-366
20. Williams D.O., Abbott J.D., and Kip K.E. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 114 (2006) 2154-2162
21. Yang Y.J., Xu B., Kang S., Pei W.D., Chen J.L., Qiao S.B., Qin X.W., Yao M., Chen J., Wu Y.J., et al. Comparison of in-hospital and long-term outcomes between a Cypher stent and a Taxus stent in Chinese diabetic patients with coronary artery disease. Chin Med J (Engl) 120 (2007) 1868-1873
22. Daemen J., Garcia-Garcia H.M., Kukreja N., Imani F., de Jaegere P.P., Sianos G., van Domburg R.T., and Serruys P.W. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 28 (2007) 26-32
23. Pinto D.S., Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Mehran R., Na Y., Turco M., et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 48 (2006) 32-36
24. Mahmud E., Bromberg-Marin G., Palakodeti V., Ang L., Creanga D., and Demaria A.N. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 51 (2008) 2385-2395
25. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351